Researchers reported a CRISPR-based method that reprograms mitochondrial function after myocardial injury, proposing a direct genetic route to restore cardiac energy metabolism. The study details how targeted edits improved mitochondrial performance in models of post-infarct heart failure, addressing a major contributor to progressive cardiac decline. In a second cardiac study, scientists showed that restoring RBM22 — an RNA-binding protein — reactivated cardiomyocyte proliferation signals previously thought shut in adult hearts. The RBM22 work demonstrated molecular and transcriptional shifts consistent with renewed regenerative capacity in preclinical models. Together these reports point to two distinct intervention strategies: correcting organelle-level bioenergetics via genome editing and resetting nuclear RNA programs to permit cardiomyocyte cell-cycle entry. Both efforts are early-stage but highlight multiple molecular entry points for therapeutic development against chronic heart failure.